Pravastatin Attenuates Ceramide-Induced Cytotoxicity in Mouse Cerebral Endothelial Cells with HIF-1 Activation and VEGF

Upregulation.

許重義

Chen SD;Hu CJ;Yang DI;Nassief A;Chen H;Yin K;Xu J;Hsu CY

Abstract

<u>Ceramide</u> is a <u>pro-apoptotic lipid</u> messenger that induces <u>oxidative stress</u> and may mediate <u>apoptosis</u> in cerebral <u>endothelial cells</u> (CECs) induced by <u>TNF-alpha/cycloheximide</u>, <u>lipopolysaccharide</u>, oxidized <u>LDL</u>, IL-1, and <u>amyloid</u> <u>peptide</u>. Exposure of CECs to C2 <u>ceramide</u> for 12 h caused <u>cell death</u> in a concentration-dependent manner, with a <u>LC50</u> of 30 microM. <u>Statins</u> are inhibitors of 3-hydroxyl-3-methyl <u>coenzyme A reductase</u> which is the <u>rate-limiting enzyme</u> for <u>cholesterol biosynthesis</u>. Pretreatment with <u>pravastatin</u> at 20 microM for 16 h substantially <u>attenuated ceramide</u> <u>cytotoxicity</u> in <u>mouse</u> CECs. Increases in <u>vascular endothelial growth factor</u> (<u>VEGF</u>) expression were detected within 1-3 h after <u>pravastatin</u> treatment. This <u>pravastatin</u> action was accompanied by the <u>activation</u> of hypoxia-inducible factor-1 (<u>HIF-1</u>), a <u>transcription factor</u> known to activate <u>VEGF</u> expression. These results raise the possibility that <u>pravastatin</u> may protect CECs against ceramide-induced death via the HIF-VEGF cascade.